<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00246025</url>
  </required_header>
  <id_info>
    <org_study_id>1160.50</org_study_id>
    <nct_id>NCT00246025</nct_id>
  </id_info>
  <brief_title>A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.</brief_title>
  <official_title>A Randomised, Parallel-group, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the comparative efficacy and safety of three different
      doses ( 110 mg, 150 mg, 220 mg) of BIBR 1048 (Dabigatran etexilate) orally, compared to
      placebo, in prevention of venous thromboembolism in patient with primary elective total knee
      replacement surgery, and to evaluate dose-response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Have a Composite Endpoint Consisting of Total Venous Thromboembolic Event (VTE) and All Cause Mortality During the Treatment Period.</measure>
    <time_frame>2 weeks study medication</time_frame>
    <description>number of participants with the composite endpoint (total Venous Thromboembolic Event (VTE) and all cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Have a Composite of Major VTE (Defined as Proximal DVT and PE) and VTE Related Mortality</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of participants with the composite of major VTE (defined as proximal DVT and PE) and VTE related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Have Proximal DVT (Deep Vein Thrombosis) During Treatment Period</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of participants who have Proximal DVT during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Symptomatic DVT (Deep Vein Thrombosis)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of Participants expressing DVT with symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Have Total DVT (Deep Vein Thrombosis) During Treatment Period</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of participants who have Total DVT during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pulmonary Embolism During Treatment Period</measure>
    <time_frame>2 weeks</time_frame>
    <description>Pulmonary embolism confirmed by pulmonary scintigraphy, pulmonary angiography or contrast CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died During Treatment Period</measure>
    <time_frame>2 weeks</time_frame>
    <description>All cause death, as adjudicated by the VTE events committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Events During Treatment Period</measure>
    <time_frame>2 weeks</time_frame>
    <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=2g/dL in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma &gt;=25 cm²
wound hematoma &gt;=100 cm²
spontaneous nose bleed &gt;5 min
macroscopic hematuria spontaneous or &gt;24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding &gt;5 min
any other bleeding event considered clinically relevant by the investigator
Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Transfusion</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood transfusion for treated and operated patients on Day of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Blood Loss</measure>
    <time_frame>Day 0</time_frame>
    <description>Volume of blood loss for treated and operated patients during surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Analyses</measure>
    <time_frame>First administration to end of study</time_frame>
    <description>Frequency of patients with possible clinically significant abnormalities.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">512</enrollment>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 110 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran etexilate 110 mg capsule, once a day, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran etexilate 150 mg capsule, once a day, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate 220 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran etexilate 110 mg capsule, 2capsules, once a day, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo capsule, once a day, oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>Dabigatran etexilate 110 mg capsule, once a day, oral administration</description>
    <arm_group_label>Dabigatran etexilate 110 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>Dabigatran etexilate 150 mg capsule, once a day, oral administration</description>
    <arm_group_label>Dabigatran etexilate 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Etexilate</intervention_name>
    <description>Dabigatran etexilate 220 mg capsule, once a day, oral administration</description>
    <arm_group_label>Dabigatran etexilate 220 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo capsule, once a day, oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria Inclusion criteria

          1. Patients scheduled to undergo a primary, unilateral elective total knee replacement

          2. Male or Female 20 years of age or order

          3. Patients weighing at least 40 kg

          4. Written informed consent prior to the start of study participation

        Exclusion criteria Exclusion criteria

          1. History of bleeding diathesis

          2. Constitutional or acquired coagulation disorders that in the investigator's judgment
             puts the patient at excessive risk for bleeding

          3. Major surgery or trauma (e.g. hip fracture) within the last 3 months

          4. Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time
             of enrollment (investigator's judgment) or history of myocardial infarction within the
             last 3 months

          5. Any history of hemorrhagic stroke or any of the following intracranial pathologies:
             bleeding, neoplasm, AV (arteriovenous) malformation or aneurysm or recent bleeding
             history

          6. Condition requiring anti-coagulant therapy

          7. Elevated AST(Aspartate Aminotransferase) , ALT(Alanine Aminotransferase), or any
             history of clinically relevant liver disease

          8. Patients with a history of clinically significant renal diseases or with elevated
             creatinine values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.50.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eniwa, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hachioji, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hirosaki, Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iida, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izumisano, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izunokuni,Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kagoshima, Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kawasaki, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kawasaki, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitakyusyu, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koshigaya,Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurume ,Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurume ,Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsue, Shimane</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyazaki, Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Musashimurayama, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Obihiro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omura, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saga, Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sagamihara, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sasebo, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sasebo, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sumida-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tomigusuku, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.50.040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsukuba , Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2005</study_first_submitted>
  <study_first_submitted_qc>October 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2005</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>November 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2010</results_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group With Placebo</title>
          <description>Patients were treated with matching Placebo.</description>
        </group>
        <group group_id="P2">
          <title>Dabigatran Etexilate 110 mg</title>
          <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
        </group>
        <group group_id="P3">
          <title>Dabigatran Etexilate 150 mg</title>
          <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
        </group>
        <group group_id="P4">
          <title>Dabigatran Etexilate 220 mg</title>
          <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="116"/>
                <participants group_id="P4" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unsuitable medical history was found</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group With Placebo</title>
          <description>Patients were treated with matching Placebo.</description>
        </group>
        <group group_id="B2">
          <title>Dabigatran Etexilate 110 mg</title>
          <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
        </group>
        <group group_id="B3">
          <title>Dabigatran Etexilate 150 mg</title>
          <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
        </group>
        <group group_id="B4">
          <title>Dabigatran Etexilate 220 mg</title>
          <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="126"/>
            <count group_id="B4" value="129"/>
            <count group_id="B5" value="512"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.3" spread="8.5"/>
                    <measurement group_id="B2" value="71.3" spread="7.9"/>
                    <measurement group_id="B3" value="70.9" spread="7.7"/>
                    <measurement group_id="B4" value="72.7" spread="6.8"/>
                    <measurement group_id="B5" value="71.6" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="109"/>
                    <measurement group_id="B5" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Have a Composite Endpoint Consisting of Total Venous Thromboembolic Event (VTE) and All Cause Mortality During the Treatment Period.</title>
        <description>number of participants with the composite endpoint (total Venous Thromboembolic Event (VTE) and all cause mortality</description>
        <time_frame>2 weeks study medication</time_frame>
        <population>Full analysis set (FAS) - Full analysis set includes all patients who were randomly assigned to the treatment, received at least one oral dose, went through surgery, had an evaluable venogram for distal and proximal DVT, or had confirmed symptomatic DVT or PE, or died.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have a Composite Endpoint Consisting of Total Venous Thromboembolic Event (VTE) and All Cause Mortality During the Treatment Period.</title>
          <description>number of participants with the composite endpoint (total Venous Thromboembolic Event (VTE) and all cause mortality</description>
          <population>Full analysis set (FAS) - Full analysis set includes all patients who were randomly assigned to the treatment, received at least one oral dose, went through surgery, had an evaluable venogram for distal and proximal DVT, or had confirmed symptomatic DVT or PE, or died.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4"/>
                    <measurement group_id="O2" value="39.6"/>
                    <measurement group_id="O3" value="32.7"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested by means of hierarchical tests. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0155</p_value>
            <p_value_desc>Multiplicity was not adjusted because of hierarchical testing from highest to lowest dose.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-16.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-30.2</ci_lower_limit>
            <ci_upper_limit>-3.4</ci_upper_limit>
            <estimate_desc>The risk differences are calculated as risk in the dabigatran groups minus risk in the placebo group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested by means of hierarchical tests. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Multiplicity was not adjusted because of hierarchical testing from highest to lowest dose.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-23.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-37.0</ci_lower_limit>
            <ci_upper_limit>-10.5</ci_upper_limit>
            <estimate_desc>The risk differences are calculated as risk in the dabigatran groups minus risk in the placebo group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested by means of hierarchical tests. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Multiplicity was not adjusted because of hierarchical testing from highest to lowest dose.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-32.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-45.4</ci_lower_limit>
            <ci_upper_limit>-19.6</ci_upper_limit>
            <estimate_desc>The risk differences are calculated as risk in the dabigatran groups minus risk in the placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Have a Composite of Major VTE (Defined as Proximal DVT and PE) and VTE Related Mortality</title>
        <description>Number of participants with the composite of major VTE (defined as proximal DVT and PE) and VTE related mortality</description>
        <time_frame>2 weeks</time_frame>
        <population>FAS-major - FAS-major includes all patients who were randomised, treated, operated, and had an evaluable venogram for proximal DVT or confirmed symptomatic proximal DVT, PE, or VTE-related death.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have a Composite of Major VTE (Defined as Proximal DVT and PE) and VTE Related Mortality</title>
          <description>Number of participants with the composite of major VTE (defined as proximal DVT and PE) and VTE related mortality</description>
          <population>FAS-major - FAS-major includes all patients who were randomised, treated, operated, and had an evaluable venogram for proximal DVT or confirmed symptomatic proximal DVT, PE, or VTE-related death.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1124</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1183</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0138</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.3</ci_lower_limit>
            <ci_upper_limit>-1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Have Proximal DVT (Deep Vein Thrombosis) During Treatment Period</title>
        <description>Number of participants who have Proximal DVT during treatment period</description>
        <time_frame>2 weeks</time_frame>
        <population>FAS−pDVT - FAS−pDVT includes all patients who were randomised, treated, operated, and had an evaluable venogram for proximal DVT or confirmed symptomatic proximal DVT.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Proximal DVT (Deep Vein Thrombosis) During Treatment Period</title>
          <description>Number of participants who have Proximal DVT during treatment period</description>
          <population>FAS−pDVT - FAS−pDVT includes all patients who were randomised, treated, operated, and had an evaluable venogram for proximal DVT or confirmed symptomatic proximal DVT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.
The dabigatran groups were compared to the placebo group.. The null hypotheses are &quot;Ho: placebo = 220mg&quot;, &quot;Ho: placebo = 150mg&quot; and &quot;Ho: placebo = 110mg&quot;. ,All comparisons were two-sided with a significance level of 5%. Confidence intervals were two-sided with a level of 95%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1124</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.
The dabigatran groups were compared to the placebo group.. The null hypotheses are &quot;Ho: placebo = 220mg&quot;, &quot;Ho: placebo = 150mg&quot; and &quot;Ho: placebo = 110mg&quot;. ,All comparisons were two-sided with a significance level of 5%. Confidence intervals were two-sided with a level of 95%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1183</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.
The dabigatran groups were compared to the placebo group.. The null hypotheses are &quot;Ho: placebo = 220mg&quot;, &quot;Ho: placebo = 150mg&quot; and &quot;Ho: placebo = 110mg&quot;. ,All comparisons were two-sided with a significance level of 5%. Confidence intervals were two-sided with a level of 95%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0138</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.3</ci_lower_limit>
            <ci_upper_limit>-1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Symptomatic DVT (Deep Vein Thrombosis)</title>
        <description>Number of Participants expressing DVT with symptoms</description>
        <time_frame>2 weeks</time_frame>
        <population>FAS−op - FAS−op includes all patients who were randomly assigned to the treatment, received at least one oral dose and went through surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Symptomatic DVT (Deep Vein Thrombosis)</title>
          <description>Number of Participants expressing DVT with symptoms</description>
          <population>FAS−op - FAS−op includes all patients who were randomly assigned to the treatment, received at least one oral dose and went through surgery.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="1.6"/>
                    <measurement group_id="O4" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested based on Fisher`s exact test.
The dabigatran groups were compared to the placebo group.. The null hypotheses are &quot;Ho: placebo = 220mg&quot;, &quot;Ho: placebo = 150mg&quot; and &quot;Ho: placebo = 110mg&quot;. ,All comparisons were two-sided with a significance level of 5%. Confidence intervals were two-sided with a level of 95%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6107</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested based on Fisher`s exact test.
The dabigatran groups were compared to the placebo group.. The null hypotheses are &quot;Ho: placebo = 220mg&quot;, &quot;Ho: placebo = 150mg&quot; and &quot;Ho: placebo = 110mg&quot;. ,All comparisons were two-sided with a significance level of 5%. Confidence intervals were two-sided with a level of 95%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested based on Fisher`s exact test.
The dabigatran groups were compared to the placebo group.. The null hypotheses are &quot;Ho: placebo = 220mg&quot;, &quot;Ho: placebo = 150mg&quot; and &quot;Ho: placebo = 110mg&quot;. ,All comparisons were two-sided with a significance level of 5%. Confidence intervals were two-sided with a level of 95%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6162</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Have Total DVT (Deep Vein Thrombosis) During Treatment Period</title>
        <description>Number of participants who have Total DVT during treatment period</description>
        <time_frame>2 weeks</time_frame>
        <population>FAS−tDVT - FAS−tDVT includes all patients who were randomised, treated, operated, and had evaluable venogram or confirmed symptomatic DVT.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Total DVT (Deep Vein Thrombosis) During Treatment Period</title>
          <description>Number of participants who have Total DVT during treatment period</description>
          <population>FAS−tDVT - FAS−tDVT includes all patients who were randomised, treated, operated, and had evaluable venogram or confirmed symptomatic DVT.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4"/>
                    <measurement group_id="O2" value="39.6"/>
                    <measurement group_id="O3" value="32.7"/>
                    <measurement group_id="O4" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.
The dabigatran groups were compared to the placebo group.. The null hypotheses are &quot;Ho: placebo = 220mg&quot;, &quot;Ho: placebo = 150mg&quot; and &quot;Ho: placebo = 110mg&quot;. ,All comparisons were two-sided with a significance level of 5%. Confidence intervals were two-sided with a level of 95%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0155</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-16.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.2</ci_lower_limit>
            <ci_upper_limit>-3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.
The dabigatran groups were compared to the placebo group.. The null hypotheses are &quot;Ho: placebo = 220mg&quot;, &quot;Ho: placebo = 150mg&quot; and &quot;Ho: placebo = 110mg&quot;. ,All comparisons were two-sided with a significance level of 5%. Confidence intervals were two-sided with a level of 95%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-23.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.0</ci_lower_limit>
            <ci_upper_limit>-10.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of dabigatran etexilate to placebo was tested. Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.
The dabigatran groups were compared to the placebo group.. The null hypotheses are &quot;Ho: placebo = 220mg&quot;, &quot;Ho: placebo = 150mg&quot; and &quot;Ho: placebo = 110mg&quot;. ,All comparisons were two-sided with a significance level of 5%. Confidence intervals were two-sided with a level of 95%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Multiplicity was not adjusted.</p_value_desc>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-32.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.4</ci_lower_limit>
            <ci_upper_limit>-19.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pulmonary Embolism During Treatment Period</title>
        <description>Pulmonary embolism confirmed by pulmonary scintigraphy, pulmonary angiography or contrast CT.</description>
        <time_frame>2 weeks</time_frame>
        <population>FAS−op</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pulmonary Embolism During Treatment Period</title>
          <description>Pulmonary embolism confirmed by pulmonary scintigraphy, pulmonary angiography or contrast CT.</description>
          <population>FAS−op</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died During Treatment Period</title>
        <description>All cause death, as adjudicated by the VTE events committee.</description>
        <time_frame>2 weeks</time_frame>
        <population>FAS−op</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died During Treatment Period</title>
          <description>All cause death, as adjudicated by the VTE events committee.</description>
          <population>FAS−op</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Events During Treatment Period</title>
        <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=2g/dL in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma &gt;=25 cm²
wound hematoma &gt;=100 cm²
spontaneous nose bleed &gt;5 min
macroscopic hematuria spontaneous or &gt;24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding &gt;5 min
any other bleeding event considered clinically relevant by the investigator
Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
        <time_frame>2 weeks</time_frame>
        <population>Safety set - Safety set includes all patients who were randomly assigned to the treatment, received at least one oral dose and went through surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Events During Treatment Period</title>
          <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=2g/dL in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma &gt;=25 cm²
wound hematoma &gt;=100 cm²
spontaneous nose bleed &gt;5 min
macroscopic hematuria spontaneous or &gt;24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding &gt;5 min
any other bleeding event considered clinically relevant by the investigator
Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
          <population>Safety set - Safety set includes all patients who were randomly assigned to the treatment, received at least one oral dose and went through surgery.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major and clinically relevant bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Placebo for the category major bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Placebo for the category major bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4960</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Placebo for the category major bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6223</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absolute difference versus Placebo for the category major and clinically relevant bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1513</p_value>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Absolute Difference (Percentage)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Absolute difference versus Placebo for the category major and clinically relevant bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1696</p_value>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Absolute Difference (Percentage)</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Absolute difference versus Placebo for the category major and clinically relevant bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7802</p_value>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Absolute Difference (Percentage)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absolute difference versus Placebo for the category any bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6313</p_value>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Absolute Difference (Percentage)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Absolute difference versus Placebo for the category any bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5377</p_value>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Absolute Difference (Percentage)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>9.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Absolute difference versus Placebo for the category any bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4493</p_value>
            <method>normal approximation method</method>
            <method_desc>Statistical inference was made on the basis of the normal approximation of two independent binomial distributions.</method_desc>
            <param_type>Absolute Difference (Percentage)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Transfusion</title>
        <description>Blood transfusion for treated and operated patients on Day of surgery.</description>
        <time_frame>Day 0</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Transfusion</title>
          <description>Blood transfusion for treated and operated patients on Day of surgery.</description>
          <population>Safety set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Autologous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homologous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autologous and homologous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Blood Loss</title>
        <description>Volume of blood loss for treated and operated patients during surgery.</description>
        <time_frame>Day 0</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Blood Loss</title>
          <description>Volume of blood loss for treated and operated patients during surgery.</description>
          <population>Safety set</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" spread="132.0"/>
                    <measurement group_id="O2" value="90.5" spread="128.0"/>
                    <measurement group_id="O3" value="67.5" spread="96.0"/>
                    <measurement group_id="O4" value="77.3" spread="130.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Analyses</title>
        <description>Frequency of patients with possible clinically significant abnormalities.</description>
        <time_frame>First administration to end of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group With Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 110 mg</title>
            <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O3">
            <title>Dabigatran Etexilate 150 mg</title>
            <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
          </group>
          <group group_id="O4">
            <title>Dabigatran Etexilate 220 mg</title>
            <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Analyses</title>
          <description>Frequency of patients with possible clinically significant abnormalities.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="122"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST increase N=(120;131;122;126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST decrease N=(120;131;122;126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increase N=(120;131;122;126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT decrease N=(120;131;122;126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin increase N=(120;130;122;127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin decrease N=(120;130;122;127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First administration to end of study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group With Placebo</title>
          <description>Patients were treated with matching Placebo.</description>
        </group>
        <group group_id="E2">
          <title>Dabigatran Etexilate 110 mg</title>
          <description>Patients were treated with 110mg dabigatran etexilate once daily.</description>
        </group>
        <group group_id="E3">
          <title>Dabigatran Etexilate 150 mg</title>
          <description>Patients were treated with 150mg dabigatran etexilate once daily.</description>
        </group>
        <group group_id="E4">
          <title>Dabigatran Etexilate 220 mg</title>
          <description>Patients were treated with 220mg dabigatran etexilate once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Post procedural infestation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Wound infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="133"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

